Evidence map›Paper›PMID 37463589›Full record

ArticlePhysics in medicine and biology2023

Validation of an MR-based multimodal method for molecular composition and proton stopping power ratio determination using

Raanan Marants, Sebastian Tattenberg, Jessica Scholey, Evangelia Kaza, Xin Miao, Thomas Benkert, Olivia Magneson, Jade Fischer, Luciano Vinas, Katharina Niepel and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Physics in medicine and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Raanan MarantsDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, United States of America.
Sebastian TattenbergDepartment of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, Garching, Germany.
Jessica ScholeyDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, California, United States of America.
Evangelia KazaDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, United States of America.
Xin MiaoSiemens Medical Solutions USA Inc., Boston, Massachusetts, United States of America.
Thomas BenkertSiemens Healthcare GmbH, Erlangen, Germany.
Olivia MagnesonDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, United States of America.
Jade FischerDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, United States of America.
Luciano VinasDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, United States of America.
Katharina NiepelDepartment of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, Garching, Germany.
Thomas BortfeldDivision of Radiation Biophysics, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
Guillaume LandryDepartment of Radiation Oncology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID 0000-0003-1707-4068
Katia ParodiDepartment of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, Garching, Germany.ORCID 0000-0001-7779-6690
Joost VerburgDivision of Radiation Biophysics, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
Atchar SudhyadhomDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, United States of America.ORCID 0000-0002-0397-0884

Funding

Fast Individualized Delivery Adaptation in Proton TherapyR01CA229178 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PAGANETTI, HARALD · 2019 to 2023
$1.5M
A Multimodal Imaging Approach Towards the Reduction of Proton Beam Range UncertaintiesR21EB026086 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SUDHYADHOM, ATCHAR · 2018 to 2020
$594k
PROTON THERAPY RESEARCH AND TREATMENT CENTERC06CA059267 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI GOITEIN, MICHAEL · 1992 to 1995
–
NCI NIH HHS C06 CA059267NCI NIH HHS R01 CA229178NIBIB NIH HHS R21 EB026086
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Brain NeoplasmsProton TherapyAnimalsCalibrationMagnetic Resonance ImagingPhantoms, ImagingProtonsRadiotherapy Planning, Computer-AssistedSwineTomography, X-Ray ComputedProtonsMRIproton therapyrange uncertaintystopping power ratio

Identifiers

PMID37463589
PMCPMC10645122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.